Challenges and opportunities in microRNA-based cancer therapeutics.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40239629.
- Also identified by DOI 10.1016/j.xcrm.2025.102057 and PMC identifier 12047499.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The 2024 Nobel Prize honored groundbreaking microRNA (miRNA) discoveries that unveiled the critical functions of miRNAs in fundamental biology and human health. Despite promising therapeutic potential, there are no Food and Drug Administration (FDA)-approved miRNA-based cancer therapies. This commentary discusses the progress and challenges of miRNA-based cancer therapeutics and their potential impact on future clinical oncology.
Medical subject headings
- MicroRNAs
- Neoplasms